Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYNTEX' FEMSTAT ANTIFUNGAL CREAM IS "APPROVABLE" IN SUSTAINED- RELEASE

Executive Summary

SYNTEX' FEMSTAT ANTIFUNGAL CREAM IS "APPROVABLE" IN SUSTAINED- RELEASE formulation. Syntex currently markets Femstat (butoconazole nitrate 2%) with an indication for use once a day over three days, extendable by an additional three days, for the treatment of vaginal yeast infections. FDA designated the new formulation "approvable" on March 31, according to the agency's compilation of NDA approvals for that month (see FDA's list of March approvals, p. 12). The new sustained-release formulation incorporates K-V Pharmaceutical's proprietary Site Release technology and will allow Syntex to make a one-time dosing claim. Bristol-Myers Squibb already markets a single-dose prescription antifungal, Vagistat-1 (tioconazole 6.5%) under a license from Fujisawa. Syntex may be looking down the line to an OTC version; currently, both antifungals approved by FDA for OTC treatment of vaginal yeast infections -- Schering-Plough's Gyne- Lotrimin (clotrimazole 1%) and Ortho's Monistat-7 (miconazole 2%) -- require multiple applications.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS020931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel